Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101)
Tetsuhiko Asao(Cornell University), Kazuhisa Takahashi(Kansai Medical University), Takehito Shukuya(Juntendo University), Kyoichi Kaira(Saitama International Medical Center), Yasushi Goto(Tennessee Oncology), Koichi Takayama(Kyoto Prefectural University of Medicine), Tomoyasu Mimori, Yukari Tsubata(Shimane University), Yoshitaka Zenke(National Cancer Center Hospital East), Satoshi Ikeda, Hideaki Mizutani(Nippon Medical School), Junko Tanizaki(Kindai University Sakai Hospital), Keita Mori(Shizuoka Cancer Center), Shunichi Sugawara(Sendai Kousei Hospital), Hiroaki Akamatsu(Army Medical University), Hiroshi Tanaka(Tokyo Medical and Dental University), Ryo Ko(Shizuoka Cancer Center), Takuji Suzuki(Chiba University), Motoko Tachihara(Kobe University)
Cited by 5
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
A cross-population atlas of genetic associations for 220 human phenotypes
|Nature Genetics|2021|2.4k